Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | OXTR | P30559 | 8/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3380254 | 0.84 | OXTR (0.41) | HTR2CHTR2BOXTRHTR6 | |
| SCHEMBL3378297 | 0.81 | HTR2A (0.43) | HTR2CHTR2AHTR2BOXTRKMT2A | |
| Hydrochloric Acid SCHEMBL6871211 | 0.80 | HTR6 (0.43) | HTR2CHTR2BOXTRHTR6 | |
| SCHEMBL3380150 | 0.78 | OXTR (0.38) | OXTRHTR6 | |
| SCHEMBL400825 | 0.78 | HTR6 (0.54) | OXTRHTR6 | |
| Hydrochloric Acid SCHEMBL2267895 | 0.77 | HTR6 (0.53) | OXTRHTR6 | |
| SCHEMBL3381685 | 0.76 | OXTR (0.41) | HTR2CHTR2BOXTRHTR6 | |
| SCHEMBL14667894 | 0.76 | CTSS (0.44) | HTR2CKMT2A | |
| Hydrochloric Acid SCHEMBL13506588 | 0.75 | CTSS (0.43) | HTR2CKMT2A | |
| SCHEMBL3377927 | 0.73 | OXTR (0.43) | HTR2CHTR2AHTR2BOXTRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497285-B1 | BENZOXAZINONE-DERIVED COMPOUNDS, THEIR PREPARATION UND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2010-11-24 | — | — | EP | claimed |
| US-20060128701-A1 | Benzoxazinone-derived compounds, their preparation and use as medicaments | JOVER ANTONI T | 2006-06-15 | — | — | US | claimed |
| EP-1497285-B1 | BENZOXAZINONE-DERIVED COMPOUNDS, THEIR PREPARATION UND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2010-11-24 | — | — | EP | disclosed |
| US-7514429-B2 | Benzoxazinone-derived compounds, their preparation and use as medicaments | ESTEVE LABORATORIOS DR. ESTEVE S.A. (ES) | 2009-04-07 | — | — | US | disclosed |
| US-20060128701-A1 | Benzoxazinone-derived compounds, their preparation and use as medicaments | JOVER ANTONI T | 2006-06-15 | — | — | US | disclosed |
| US-7056914-B2 | Benzoxazinone-derived compounds, their preparation and use as medicaments | ESTEVE LABORATORIOS DR. ESTEVE S.A. (ES) | 2006-06-06 | — | — | US | disclosed |
| US-20040058920-A1 | Benzoxazinone-derived compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE,S.A. (ES) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128701-A1 | Benzoxazinone-derived compounds, their preparation and use as medicaments | XDH, CYP3A5, CYP4X1 | HTR2C 806/4885HTR2A 1338/4885HTR2B 1326/4885 |
| US-20040058920-A1 | Benzoxazinone-derived compounds, their preparation and use as medicaments | XDH, CYP3A5, CYP4X1 | HTR2C 806/4885HTR2A 1338/4885HTR2B 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.